GfK adds payer expert Bridgehead to its roster

Share this article:
Timothy Fitzgerald
Timothy Fitzgerald
GfK bought market access counselor Bridgehead International for an undisclosed sum.

The consultancy now operates as GfK Bridgehead. GfK said Bridgehead generated 2011 sales of €12.12 million ($16 million).

In a statement, GfK chief operating officer Debra Pruent termed the acquisition “an important strategic investment” at a time when governments, insurance companies and other healthcare providers are stepping up use of pricing and reimbursement controls. The acquisition comes on the heels of GfK's purchase of Knowledge Networks in December.

With Bridgehead, GfK gets access to that firm's global payer panel and US online portal. In an e-mail to clients, GfK touted Bridgehead's ability to provide support in pricing, reimbursement, health economics and market access, plus its knowledge of local healthcare systems.

Timothy Fitzgerald will remain in his role as Bridgehead managing director, as will the rest of his executive team. Pharma, device and diagnostics clients, said Fitzgerald in the statement, are seeking to “hard-wire market access and payer insights into their R&D, portfolio, business development, commercialization and life cycle strategies.”

GfK also pledged to grow Bridgehead's staff of 60 and to keep US offices in Boston, San Francisco and New York City, as well as London and Melton Mowbray, UK.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.